FY2025, Strategic Reset and Platform Establishment
The 2025 financial year represented a deliberate strategic reset, during which management prioritised strengthening the Group's capital structure, simplifying legacy financing arrangements, and establishing the operational foundations required to support scalable growth.
During the period, the Company executed a number of key initiatives, including:
Securing cornerstone funding to strengthen the balance sheet
Streamlining elements of its capital structure, including the accelerated resolution of legacy convertible financing arrangements
Consolidating its supply chain and inventory positioning, including transitioning manufacturing activities back to Australia to enhance quality control and support its flagship brands
Advancing its HealthTech platform and multi-channel distribution model
Continuing the development of its core brands, including SystemLS and Azurene
These actions were undertaken to position the Company for sustainable growth. While supply chain consolidation and inventory realignment resulted in a short-term impact on revenue, this reflects the Company's deliberate prioritisation of restructuring and platform development over near-term sales activity, and was critical in establishing a more robust and scalable operating platform.
The Board believes these measures have strengthened operational control, product quality and the Company's ability to scale as a trusted provider of evidence-based nutrition solutions globally. These initiatives are expected to support revenue growth as they begin to flow through to topline performance in 2026.
Positioned for Execution
The Company exits FY2025 ...
